Patents by Inventor Luke Evnin

Luke Evnin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220220181
    Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.
    Type: Application
    Filed: February 22, 2022
    Publication date: July 14, 2022
    Inventors: William WINSTON, Luke EVNIN, Vinay BHASKAR, Giselle KNUDSEN, Daniel J. HICKLIN, Cynthia SEIDEL-DUGAN, Jose Andres SALMERON GARCIA, Heather R. BRODKIN
  • Patent number: 11352403
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: June 7, 2022
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20220056096
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 24, 2022
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Publication number: 20210403524
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 14, 2021
    Publication date: December 30, 2021
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN, Cynthia SEIDEL-DUGAN
  • Patent number: 11078280
    Abstract: Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: August 3, 2021
    Assignee: Oncorus, Inc.
    Inventors: Luke Evnin, Mitchell H. Finer
  • Publication number: 20210179735
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Vanitha RAMAKRISHNAN, Holger WESCHE
  • Publication number: 20210115102
    Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.
    Type: Application
    Filed: October 28, 2020
    Publication date: April 22, 2021
    Inventors: William WINSTON, Luke EVNIN, Vinay BHASKAR, Giselle KNUDSEN, Daniel HICKLIN, Cynthia SEIDEL-DUGAN, Jose Andres SALMERON GARCIA, Heather BRODKIN
  • Publication number: 20210085735
    Abstract: Described herein are oncolytic viruses comprising one or more nucleic acids encoding an engager molecule. In some embodiments, the oncolytic viruses comprise one or more nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the oncolytic virus and methods of treating cancer using the oncolytic viruses are further provided herein.
    Type: Application
    Filed: December 28, 2018
    Publication date: March 25, 2021
    Inventors: Mitchell H. FINER, Luke EVNIN
  • Patent number: 10954311
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
  • Publication number: 20210032339
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: August 10, 2020
    Publication date: February 4, 2021
    Inventors: Luke Evnin, Jeanmarie Dean Guenot, Lori Kunkel
  • Publication number: 20210024654
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 18, 2020
    Publication date: January 28, 2021
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Publication number: 20200283490
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20200283489
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Patent number: 10738118
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 11, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Luke Evnin, Jeanmarie Guenot, Lori Kunkel
  • Publication number: 20200231672
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 23, 2020
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan LEMON
  • Patent number: 10696724
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Patent number: 10696723
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Publication number: 20200157221
    Abstract: Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.
    Type: Application
    Filed: January 28, 2020
    Publication date: May 21, 2020
    Inventor: Luke EVNIN
  • Patent number: 10626190
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Publication number: 20200115461
    Abstract: Provided herein are immune cells engineered to express one or more cell surface receptor polypeptides containing activatable antigen receptor polypeptides, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: May 3, 2018
    Publication date: April 16, 2020
    Inventors: Luke EVNIN, Holger WESCHE, Kevin WRIGHT